No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 40 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:01:19.198Z. Latest historical point 2022-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Decoy Therapeutics Inc. (DCOY) stock was $1.58 as of Oct 6, 2026, 2:56 PM EDT, down 5.39% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -96.5% · 3-year avg -87.9%/yr · 5-year avg -86.4%/yr
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs.
Biotechnology · Houston, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2020-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-2.59
Revenue Est.
N/A
Last Quarter Results
EPS
$-4.46
vs Estimate
$-2.88
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DCOY | $840,509 | $1.58 | -5.39% | -96.49% | -86.39% | -79.17% | N/A |
| 2RDGT | $834,376 | $0.93 | +4.70% | -99.53% | -86.91% | -67.34% | vs DCOY |
| 3BBLG | $850,879 | $0.47 | -3.13% | -80.44% | N/A | N/A | vs DCOY |
| 4BJDX | $857,157 | $0.83 | +8.83% | -87.52% | N/A | N/A | vs DCOY |
| 5SBFM | $858,572 | $0.36 | -14.07% | N/A | N/A | N/A | vs DCOY |
| 6GCTK | $901,902 | $1.13 | +1.80% | -98.99% | -92.60% | -77.25% | vs DCOY |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$3.00
+89.9% upside
Low
$3.00
Current
$1.58
High
$3.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.59 | $-2.59 | $-2.59 | 1 |
| Quarter ending Dec 2026 | $-1.11 | $-1.11 | $-1.11 | 1 |
| Quarter ending Mar 2027 | $-2.16 | $-2.16 | $-2.16 | 1 |
| Quarter ending Jun 2027 | $-2.22 | $-2.22 | $-2.22 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-8.96 | $-8.96 | $-8.96 | 1 |
| FY 2027 | $-8.28 | $-8.28 | $-8.28 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $11.88M | $11.88M | $11.88M | 1 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
